Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Biomaterials. 2022 Dec 24;293:121960. doi: 10.1016/j.biomaterials.2022.121960

Figure 8. ND vs. Diseased vECM Lung ECM Composition.

Figure 8.

Proteomic analysis of vECM samples obtained from ND (n=6), COPD (n=3), and IPF (n=3) decellularized patient lung lobes. (A) Schematic depicting samples utilized for proteomic analysis. (B) PCA plot demonstrating similarity of vECM protein composition across lung conditions. Each data point represents the relative abundance (%) of all individual vECM proteins (normalized to abundance of total vECM composition) within each respective sample.(C) Relative abundance (%) of vECM protein type (normalized to total vECM composition within each respective sample) within each respective sample). (D) Comparison of normalized individual vECM proteins across lung conditions. Bars in (C,D) indicate mean +/− SEM; *p<0.05, **p<0.01 using Dunn’s method. Statistical trends are identified if 0.05≤p<0.1. (E) Venn diagram depicting differences in vECM proteins of pooled samples by condition.